Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
企業コードGCTK
会社名GlucoTrack Inc
上場日Apr 09, 2013
最高経営責任者「CEO」Goode (Paul V)
従業員数11
証券種類Ordinary Share
決算期末Apr 09
本社所在地301 Rt 17 North
都市RUTHERFORD
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号07070
電話番号197286757878
ウェブサイトhttps://glucotrack.com/
企業コードGCTK
上場日Apr 09, 2013
最高経営責任者「CEO」Goode (Paul V)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし